

**IN THE MATTER OF** \* **BEFORE THE MARYLAND**  
**BRITTANY C. HUDGINS** \* **STATE BOARD OF PHARMACY**  
**PHARMACY TECHNICIAN** \*  
**RESPONDENT** \* **CASE NO: 24-047**  
**REGISTRATION NO.: T21147** \*

\* \* \* \* \*

**ORDER FOR SUMMARY SUSPENSION**

The Maryland State Board of Pharmacy (the “Board”) hereby **SUMMARILY SUSPENDS** the registration of **Brittany C. Hudgins** (the “Respondent”), Registration Number: **T21147**, to practice as a pharmacy technician in the State of Maryland under the Maryland Pharmacy Act (the “Act”), Md. Code Ann., Health Occ. (“Health. Occ.”) §§12-101 *et seq.* (2022 Repl. Vol. & 2023 Supp.).

The Board takes such action pursuant to its authority under Md. Code Ann., State Gov’t § 10-226(c) (2022 Repl. Vol. & 2023 Supp.), concluding that the public health, safety, or welfare imperatively requires emergency action.

**INVESTIGATIVE FINDINGS**

Based on information received by, and made known to the Board, and the investigatory information obtained by, received by, and made known to and available to

the Board, including the instances described below, the Board has reason to believe that the following facts are true.<sup>1</sup>

1. At all times relevant hereto, the Respondent was registered to practice as a pharmacy technician in the State of Maryland.

2. The Respondent was originally issued a registration to practice as a pharmacy technician in Maryland on or about June 15, 2018. The Respondent's registration expired on October 31, 2023, and has not been renewed.

3. At all times relevant hereto, the Respondent was employed at a retail pharmacy chain (the "Pharmacy")<sup>2</sup> located in Maryland.

4. On or about April 26, 2023, the Board received notification from Pharmacy staff that the Respondent diverted medication from the Pharmacy. Pharmacy staff submitted DEA Form 106 - Report of Theft or Loss of Controlled Substances indicating that 268 tablets of Lorazepam 0.5 mg; 19 tablets of Diazepam 2 mg; 1 tablet of Oxycodone HCL(IR) 15 mg; 274 tablets of Alprazolam 0.25mg; 264 tablets of Alprazolam 0.5 mg; and 19 tablets of Oxycontin ER 30 mg.<sup>3</sup>

5. On or about February 23, 2023, the Respondent was interviewed by Pharmacy staff.

---

<sup>1</sup> The statements regarding the Respondent's conduct are only intended to provide the Respondent with notice of the basis for the Board's action. They are not intended as, and do not necessarily represent a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in this matter.

<sup>2</sup> For confidentiality and privacy purposes, the names of Pharmacy staff and the Pharmacy involved in this case are not disclosed in this document. Upon written request, the Administrative Prosecutor will provide the information to the Respondent.

<sup>3</sup> Lorazepam, Diazepam, and Alprazolam are each Schedule IV Controlled Dangerous Substances ("CDS"). Oxycodone and Oxycontin are both Schedule II CDS.

6. The Respondent provided a written statement to the Pharmacy confirming that she took multiple medications from the Pharmacy. The Respondent admitted in her written statement that she diverted Diazepam; Diltiazem; Trazadone 300mg; Xanax 2.5 mg; and Xanax 5 mg.

7. Following her interview, the Respondent was terminated by the Pharmacy.

### **CONCLUSIONS OF LAW**

Based on the foregoing Investigative Findings, the Board concludes that the public health, safety, or welfare imperatively requires emergency action in this case, pursuant to Md. Code Ann., State Gov't. § 10-226(c) (2) (2021 Repl. Vol. & 2023 Supp.).

### **ORDER**

Based on the foregoing Investigative Findings and Conclusions of Law, it is this 17<sup>th</sup> day of January 2024, by a majority of the quorum of the Board, it is hereby

**ORDERED** that the registration issued to the Respondent to practice as a pharmacy technician in the State of Maryland under registration number: T21147 is hereby **SUMMARILY SUSPENDED**; and it is further

**ORDERED** that the Respondent is prohibited from practicing as a pharmacy technician in the State of Maryland; and it is further

**ORDERED** that the Respondent has the opportunity to appear before the Board for a post-deprivation show cause hearing for a determination of whether the Summary Suspension should be continued. A request for a post-deprivation show cause hearing

must be made in writing to the Board and be made **WITHIN THIRTY (30) CALENDAR DAYS** of the date of this Order; and it is further

**ORDERED** that if the Respondent fails to request a post-deprivation show cause hearing in writing in a timely manner, or if the Respondent requests a post-deprivation show cause hearing but fails to appear before the Board when the hearing is scheduled, the Respondent's registration shall remain **SUSPENDED**; and it is further

**ORDERED** that the Respondent shall immediately return all registrations (wall and wallet sized) to the Board; and it is further

**ORDERED** that this Order for Summary Suspension is a **PUBLIC** document, as defined in Md. Code Ann., General Provision §§ 4-101 *et seq.* & § 4-333 (2022 Rep. Vol. & 2023 Supp.).

1-17-24  
Date

  
Deena Speights-Napata, M.A.  
Executive Director for  
Neil B. Leikach, PD  
Board President  
Maryland State Board of Pharmacy